Predict your next investment

HEALTHCARE | Drug Development
tktx.com

See what CB Insights has to offer

Stage

Acq - P2P | Acquired

Total Raised

$25M

Valuation

$0000 

About Transkaryotic Therapies

Transkaryotic Therapies (NASDAQ: TKTX) develops technologies for the production of human proteins and for gene therapy systems. Products developed with these technologies include ReplagalT, a drug approved for the treatment of Fabry Disease; and ElapraseT, a product awaiting approval for Hunter syndrome.

Transkaryotic Therapies Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Transkaryotic Therapies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Transkaryotic Therapies is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.